Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Date: January 1, 2012
Pages: 66
Price:
US$ 3,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G4258865211EN
Leaflet:

Download PDF Leaflet

Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Gaucher's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Gaucher's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gaucher's Disease Therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Gaucher's Disease Therapeutics market. Its scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gaucher's Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Gaucher's Disease Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gaucher's Disease Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Gaucher's Disease Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Gaucher's Disease Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gaucher's Disease Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global Gaucher's Disease Therapeutics market landscape? - Identify, understand and capitalize.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 GAUCHER’S DISEASE THERAPEUTICS - INTRODUCTION

2.1 Disease Overview
  2.1.1 Types of Gaucher’s Disease
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Signs and Symptoms
  2.5.1 Type 1 Gaucher’s Disease Clinical Manifestation
  2.5.2 Type 2 Gaucher’s Disease Clinical Manifestation
  2.5.3 Type 3 Gaucher’s Disease Clinical Manifestation
2.6 Commonly Used Diagnostic Tests
  2.6.1 Commonly Diagnostic Tests
2.7 Treatment and Management Options for Gaucher’s Disease
  2.7.1 Types of Therapeutics Options
2.8 GlobalData Pipeline Report Guidance

3 GAUCHER’S DISEASE THERAPEUTICS - MARKET CHARACTERIZATION

3.1 Gaucher’s Disease Therapeutics Market Size (2005 - 2010) - Global
3.2 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - Global
3.3 Gaucher’s Disease Therapeutics Market Size (2005 - 2010) - The US
3.4 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - The US
3.5 Gaucher’s Disease Therapeutics Market Size (2005 - 2010) - France
3.6 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - France
3.7 Gaucher’s Disease Therapeutics Market Size (2005-2010) - Germany
3.8 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - Germany
3.9 Gaucher’s Disease Therapeutics Market Size (2005 - 2010) - Italy
3.10 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - Italy
3.11 Gaucher’s Disease Therapeutics Market Size (2005 - 2010) - Spain
3.12 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - Spain
3.13 Gaucher’s Disease Therapeutics Market Size (2005 - 2010) - The UK
3.14 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - The UK
3.15 Gaucher’s Disease Therapeutics Market Size (2005 - 2010) - Japan
3.16 Gaucher’s Disease Therapeutics Market Forecast (2010 - 2018) - Japan
3.17 Drivers and Barriers for the Gaucher’s Disease Therapeutics Market
  3.17.1 Drivers for the Gaucher’s Disease Therapeutics Market
  3.17.2 Barriers for the Gaucher’s Disease Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 GAUCHER’S DISEASE THERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Marketed Products in the Gaucher’s Disease Therapeutics Market
  4.3.1 Cerezyme (imiglucerase)
  4.3.2 Zavesca (miglustat)
  4.3.3 Vpriv (velaglucerase alfa)
4.4 Key Takeaway

5 GAUCHER'S DISEASE THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Gaucher’s Disease Therapeutics Pipeline - Pipeline by Phases of Development
  5.3.1 Gaucher’s Disease Therapeutics - Regulatory Filed and Phase III Clinical Pipeline
  5.3.2 Gaucher’s Disease Therapeutics - Phase II Pipeline
  5.3.3 Gaucher’s Disease Therapeutics - Preclinical
5.4 Technology Trends Analytic Framework
5.5 Gaucher's Disease Therapeutics Market - Pipeline by Mechanism of Action
5.6 Gaucher's Disease Therapeutics - Promising Drugs in Clinical Development
5.7 Molecule Profile for Promising Drugs in Clinical Development
  5.7.1 Uplyso (taliglucerase alfa)
  5.7.2 Eliglustat tartrate(Genz-112638)
  5.7.3 ISU302
5.8 Key Takeaway

6 GAUCHER’S DISEASE THERAPEUTICS - CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Region and Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials Mapping by Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Gaucher’s Disease Therapeutics Clinical Trials

7 GAUCHER’S DISEASE THERAPEUTICS - STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Gaucher’s Disease Therapeutics - Implications for Future Market Competition

8 GAUCHER’S DISEASE THERAPEUTICS MARKET - FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
  8.2.1 Pfizer Inc.
  8.2.2 Protalix BioTherapeutics, Inc.
  8.2.3 ISU ABXIS Co., Limited
  8.2.4 Sanofi
  8.2.5 Actelion Limited
  8.2.6 Shire Plc

9 GAUCHER’S DISEASE THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS

10 GAUCHER’S DISEASE THERAPEUTICS - APPENDIX

10.1 Market Definitions
10.2 Acronyms
10.3 Research Methodology
  10.3.1 Coverage
  10.3.2 Secondary Research
  10.3.3 Forecasting
  10.3.4 Primary Research
  10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

LIST OF TABLES

Table 1: Clinical Subtypes and Manifestations of Gaucher’s Disease
Table 2: Clinical Manifestations of Gaucher’s Disease
Table 3: Gaucher’s Disease Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 4: Gaucher’s Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 5: Gaucher’s Disease Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 6: Gaucher’s Disease Therapeutics Market, The US, Forecasts ($m), 2010 - 2018
Table 7: Gaucher’s Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 8: Gaucher’s Disease Therapeutics Market, France, Forecasts ($m), 2010 - 2018
Table 9: Gaucher’s Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 10: Gaucher’s Disease Therapeutics Market, Germany, Forecasts ($m), 2010 - 2018
Table 11: Gaucher’s Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 12: Gaucher’s Disease Therapeutics Market, Italy, Forecasts ($m), 2010 - 2018
Table 13: Gaucher’s Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 14: Gaucher’s Disease Therapeutics Market, Spain, Forecasts ($m), 2010 - 2018
Table 15: Gaucher’s Disease Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 16: Gaucher’s Disease Therapeutics Market, The UK, Forecasts ($m), 2010 - 2018
Table 17: Gaucher’s Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 18: Gaucher’s Disease Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018
Table 19: Major Marketed Products in Gaucher’s Disease Therapeutics Market
Table 20: Gaucher’s Disease Therapeutics - Regulatory Filed and Phase III Pipeline, 2011
Table 21: Gaucher’s Disease Therapeutics - Phase II Pipeline, 2011
Table 22: Gaucher’s Disease Therapeutics - Preclinical Phase Pipeline, 2011
Table 23: Gaucher’s Disease Therapeutics - Most Promising Drug in Clinical Development, 2011
Table 24: Gaucher’s Disease Therapeutics - Clinical Trials by Country, 2011
Table 25: Gaucher’s Disease Therapeutics - Clinical Trials by Phase, 2011
Table 26: Gaucher’s Disease Therapeutics - Clinical Trials by Status, 2011
Table 27: Gaucher’s Disease Therapeutics - Overall Sponsors, 2011
Table 28: Gaucher’s Disease Therapeutics - Prominent Sponsors, 2011
Table 29: Gaucher’s Disease Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 30: Pfizer Inc., Pipeline - 2011
Table 31: Protalix BioTherapeutics, Inc., Pipeline - 2011
Table 32: ISU ABXIS Co., Ltd., Pipeline - 2011
Table 33: Gaucher’s Disease - Global, Deals, 2011

LIST OF FIGURES

Figure 1: Gaucher’s Disease Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 2: Gaucher’s Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 3: Gaucher’s Disease Therapeutics Market, The US, Forecast ($m), 2005 - 2010
Figure 4: Gaucher’s Disease Therapeutics Market, The US, Forecasts ($m), 2010 - 2018
Figure 5: Gaucher’s Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 6: Gaucher’s Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 7: Gaucher’s Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 8: Gaucher’s Disease Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 9: Gaucher’s Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 10: Gaucher’s Disease Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 11: Gaucher’s Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 12: Gaucher’s Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 13: Gaucher’s Disease Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 14: Gaucher’s Disease Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 15: Gaucher’s Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 16: Gaucher’s Disease Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018
Figure 17: Opportunity and Unmet Need in the Gaucher’s Disease Therapeutics Market
Figure 18: Gaucher’s Disease Therapeutics - Strategic Competitor Assessment, 2011
Figure 19: Gaucher’s Disease Therapeutics - Pipeline by Phase of Development, 2011
Figure 20: Gaucher’s Disease Therapeutics - Technology Trends Analytics Framework, 2011
Figure 21: Gaucher’s Disease Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 22: Gaucher's Disease Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 23: Gaucher’s Disease Therapeutics - Clinical Trials by Country, 2011
Figure 24: Gaucher’s Disease Therapeutics - Clinical Trials by Phase, 2011
Figure 25: Gaucher’s Disease Therapeutics - Clinical Trials by Status, 2011
Figure 26: Gaucher’s Disease Therapeutics - Overall Sponsors, 2011
Figure 27: Gaucher’s Disease Therapeutics - Prominent Sponsors, 2011
Figure 28: Gaucher’s Disease Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 29: Gaucher’s Disease Therapeutics Market, Drivers and Barriers, 2011
Figure 30: Implications for Future Market Competition in the Gaucher’s Disease Therapeutics Market, 2011
Figure 31: Gaucher’s Disease Therapeutics Market - Clinical Pipeline by Company, 2011
Figure 32: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Pfizer Inc.
Protalix BioTherapeutics, Inc.
ISU ABXIS Co., Limited
Sanofi
Actelion Limited
Shire Plc

Ask Your Question

Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: